Despite decades of progress, HIV infection remains a major global health challenge, affecting nearly 40 million people worldwide. Current treatments require lifelong daily medication and do not eliminate the virus from the body. This places a continuous burden on healthcare systems, patients, and society. This thesis explores a next-generation immunotherapy approach that aims to offer a functional cure by training the body’s own immune cells to find and destroy HIV-infected cells. Using genetic engineering, a new type of CAR-T cell that not only targets infected cells but also produces virus-blocking antibodies, was developed. This dual-action strategy aims to eliminate already infected cells, while preventing HIV from infecting healthy cells. If successful in future studies, this could lead to long-term HIV control without the need for daily medication. The societal impact of this research is most relevant to the public health and biotech/pharmaceutical sectors. Patients would benefit most directly, through improved quality of life, reduced treatment burden, and decreased stigma. At the same time, the strain of lifelong ART on healthcare systems could be reduced. In the longer term, this strategy could contribute to global HIV eradication efforts by offering a durable, one-time alternative to continuous daily medication. By laying the groundwork for a new generation of HIV therapies, this thesis contributes to a future where living with HIV no longer means a lifetime of treatment.